Thumbs up: Cancer drug R&D is exploding, get ready for the pricing debate to follow
I arrived in Chicago last night, still trying to sort out how to prioritize the news coming out of ASCO this weekend. In the lead up, I had a chance to do a pair of stories that looked at new reports covering the rapid proliferation of PD-(L)1 combos along with a 7.7% one-year growth rate in late-stage cancer drug studies, coming in at 631 pivotal-stage efforts.
This didn’t happen by accident.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.